Table 3 Adverse Event Values
Parameter | Value | Data Source |
|---|---|---|
Adverse Event Rates for EPS | ||
   Olanzapine | 15.5% | Carlson et al., 2003 [67] |
   Risperidone | 24.7% |  |
   Quetiapine | 8.0% | Package insert, revised 10/2007 |
   Ziprasidone | 14.0% | Package insert, revised 07/2007 |
   Aripiprazole | 21.0% | Fleischhacker et al., 2008 [68] |
Adverse Event Rates for Clinically Significant Weight Gain (≥ 7%) | ||
   Olanzapine | 30.0% |  |
   Risperidone | 14.0% | Lieberman et al., 2005 [23] |
   Quetiapine | 16.0% |  |
   Ziprasidone | 7.0% |  |
   Aripiprazole | 7.3% | Fleischhacker et al., 2008 [68] |
Adverse Event Rates for Diabetes | ||
   Olanzapine | 3.3% |  |
   Risperidone | 3.2% | Lambert et al., 2006 [69] |
   Quetiapine | 3.6% |  |
   Ziprasidone | 2.0% | Assumed equal to Lambert et al., 2006 [69] lowest reported rate, that for typicals |
   Aripiprazole | 2.0% |  |
Adverse Event Rates for Hyperlipidemia | ||
   Olanzapine | 16.8% |  |
   Risperidone | 14.0% | Lieberman et al., 2005 [23] |
   Quetiapine | 14.1% | Lambert et al., 2005 [70] |
   Ziprasidone | 8.1% | Olfson et al., 2006 [71] |
   Aripiprazole | 3.6% |  |